KK
TRVI icon

KLP Kapitalforvaltning’s Trevi Therapeutics TRVI Stock Holding History

KLP Kapitalforvaltning’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405K Buy
21,700
+3,400
+19% +$49.4K ﹤0.01% 1595
2026
Q1 		$218K Hold
18,300
– – ﹤0.01% 1787
2025
Q4 		$229K Buy
18,300
+900
+5% +$10.4K ﹤0.01% 1788
2025
Q3 		$159K Buy
+17,400
New +$130K ﹤0.01% 1900

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

KLP Kapitalforvaltning's TRVI Position: Q2 2026 in Review

KLP Kapitalforvaltning increased its Trevi Therapeutics (TRVI) stake by 19% in Q2 2026, buying an estimated $49.4K and bringing the position to 21,700 shares worth $405K. The position accounts for ﹤0.01% of the portfolio, ranked #1595.

KLP Kapitalforvaltning first reported a position in TRVI in Q3 2025 and has held it in 4 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • KLP Kapitalforvaltning held 21,700 shares of Trevi Therapeutics worth $405K as of Q2 2026.
  • KLP Kapitalforvaltning bought 3,400 Trevi Therapeutics shares in Q2 2026, an estimated $49.4K.
  • Trevi Therapeutics made up ﹤0.01% of KLP Kapitalforvaltning's portfolio in Q2 2026, its #1595 holding.
  • KLP Kapitalforvaltning first reported a position in Trevi Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on KLP Kapitalforvaltning's 13F filing for Q2 2026, filed 12 Aug 2026.